Rapid antidepressant effects of psilocybin without increased SV2A binding: baseline binding predicts response

We report a pre-registered [11C]UCB-J PET sub-study of a recently published randomized trial in which a single psilocybin dose produced rapid and sustained antidepressant effects in major depressive disorder (MDD). Synaptic loss has been implicated in MDD, and psychedelics induce synaptic remodeling in preclinical models within 24 hours, raising the possibility that psilocybin's antidepressant effects involve increased synaptic density. We used the PET radioligand [11C]UCB-J targeting synaptic vesicle glycoprotein 2A (SV2A) to test this in thirty-five participants with moderate-to-severe recur

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.